Clinical trial
A Phase I Study of Temozolomide, Thalidomide, and Lomustine (TTL) in Patients With Metastatic Melanoma in the Brain
NCT00527657 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of Temozolomide, Thalidomide, and Lomustine (TTL) in Patients With Metastatic Melanoma in the Brain
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 9, 2006
- Completion date
- February 2, 2012
- Enrollment
- 17 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.